About: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 July 2007

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 2007 (uk) artículu científicu espublizáu en xunetu de 2007 (ast) scientific article published on 01 July 2007 (en)
publication date	wds:Q80688403-5584EA42-8B93-4651-B824-CE464003F48F
publication date	2007-07-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q80688403-BF012D64-6C48-40C8-82AE-37185310685B
language of work or name	English
cites work	wds:Q80688403-01A48DA7-11EF-42BA-A315-1B65681B4A50 wds:Q80688403-0AC4DA4A-0E4D-433A-8076-FF83B2255364 wds:Q80688403-188A5F1B-FBDE-4A7C-A911-5AD080487DC0 wds:Q80688403-2677CE2F-D855-4CEF-8D93-872D831BEB4E wds:Q80688403-281473C0-D8C5-4FB8-B297-8AFD233BA664 wds:Q80688403-2C50F5EF-DFE9-449F-B7B1-903BD2B482F5 wds:Q80688403-42669080-AF24-4BED-A405-AE91C35EED20 wds:Q80688403-65265688-17CA-44B3-98A2-823818DEBB8D wds:Q80688403-7C9A0006-09AA-4308-ACB8-0600E7823423 wds:Q80688403-94611C3B-40AB-46C4-A5D7-248851B273FD wds:Q80688403-9B762092-319A-40C1-86B7-7F3AD1A5A00A wds:Q80688403-A3EBB094-9B8F-4935-8854-E54F0E16CF3C wds:Q80688403-A5FFC32F-5DDA-487B-8FBA-6C51203F73F1 wds:Q80688403-BCCD4957-5EDB-4207-ACD1-8EE29F2DFF0C wds:Q80688403-BF8BB7E6-94E8-4016-A1FF-55564F60E717 wds:Q80688403-C0BD1531-88C7-43BE-AA3C-C15D81491980 wds:Q80688403-CED21AA9-9A5D-4EE4-90E7-49689D126D71 wds:Q80688403-D0E17CBF-FFED-4ED2-937F-E6B1107A036F wds:Q80688403-D5337F16-1847-410D-A534-3CFF2B89289B wds:Q80688403-D57C0E02-F2D2-455D-A3BD-5F2D5E230F8A wds:Q80688403-DEC068D1-6010-4D9D-A97D-2F9549A5C638 wds:Q80688403-E1C81BB7-42CE-4BCF-AA49-798AC9EEF958 wds:Q80688403-F0A1F1DB-5B12-4C27-AFD2-59D986F5D1EA wds:Q80688403-F4CCDD38-D0E3-4D21-8005-45E4E1A0657A wds:Q80688403-F4D35795-59B5-4B17-A744-32C3E5EC34E8 wds:Q80688403-F8F16FA3-FA90-41A3-BCEF-DC0655DCE391 wds:Q80688403-F9264E19-8D79-4CA9-8081-4009D89DCFA4
cites work	Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril Inhibition of renin secretion by angiotensin. II. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Associati Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension Renin inhibition: what are the therapeutic opportunities? Changes in endocrine activities relative to obesity in patients with essential hypertension Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
author name string	wds:Q80688403-1886D761-78A8-49BC-A2AE-DF8ECF8D1D1E wds:Q80688403-55341F5B-3AE1-451F-887F-7E7A6AACBE13 wds:Q80688403-6E94702D-94D6-482B-BD6A-0F7DC6EE8DE9 wds:Q80688403-7389B3C6-DEAB-4BCC-B260-47AC18FE36AF wds:Q80688403-98A16CCD-6EAC-49E9-9FAF-808AE6785BA6
author name string	Andrew Satlin Jack Zhang Hui Fang Samir Patel Steven A Yarows
rdfs:label	Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial (en) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial (nl)
skos:prefLabel	Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial (en) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial (nl)
name	Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial (en) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial (nl)
author	wds:Q80688403-FA6CB06B-0D75-4093-9A89-91CAEF1AD2A9
author	Suzanne Oparil
title	wds:Q80688403-34E32F4C-8204-44FA-9B72-1DEC5B8965CA
title	Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial (en)
page(s)	wds:Q80688403-32C7C152-6DE1-4722-B7E1-7C1DDB02D901
page(s)	221-229
instance of	wds:Q80688403-40A9F4F1-87EA-447D-AD54-1111E384EAC4
instance of	scholarly article
main subject	wds:Q80688403-738419C3-B0DF-4A79-BAFC-7B0378B1B500
main subject	hypertension
PubMed ID	wds:Q80688403-18DAD5F7-C12C-4603-89B5-F55263F54EFB
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17658393
PubMed ID	17658393
published in	wds:Q80688403-C2DA7D35-44D5-48DF-8A3B-2F4599B1DA47
published in	The Lancet
issue	wds:Q80688403-FF4C639E-3C9D-4324-A0DC-BAEBCF5B32FE
volume	wds:Q80688403-9D11B78C-63B7-4D7B-9169-B25BE9E89FD8
issue	9583
volume	370
DOI	wds:Q80688403-A89ECF7F-C5E3-4E69-9B62-E4A4E59293A7
DOI	http://dx.doi.org/10.1016/S0140-6736(07)61124-6

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software